ANGIOGENESIS INHIBITOR-CONJUGATED ANTI-C3B ANTIBODY OR ANTI-C5 ANTIBODY AND USE THEREOF

The present invention relates to a fusion protein comprising an anti-C3b antibody or an anti-C5 antibody and an angiogenesis inhibitor, and a composition for treating eye diseases, particularly macular degeneration, by using same. The protein may not only inhibit complement-related pathways, but can...

Full description

Saved in:
Bibliographic Details
Main Authors LEE, Byoung Chul, CHUNG, Eu Ddeum, KIM, Donggeon, CHANG, Jihoon, RYU, Soomin
Format Patent
LanguageEnglish
Published 04.07.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a fusion protein comprising an anti-C3b antibody or an anti-C5 antibody and an angiogenesis inhibitor, and a composition for treating eye diseases, particularly macular degeneration, by using same. The protein may not only inhibit complement-related pathways, but can also efficiently regulate angiogenesis. Therefore, the fusion protein dimer can be effectively used to treat and prevent complement-related diseases, particularly eye diseases such as macular degeneration, and thus has high industrial applicability.
Bibliography:Application Number: AU20220430428